Back to Agenda
BIOSIMILARS: DEVELOPING A MORE THOROUGH UNDERSTANDING OF A KNOWN ACTIVE SUBSTANCE
Session Chair(s)
Virginia Acha, PhD, MSc
AVP, Global Regulatory Policy
Merck Sharp & Dohme LLC, United Kingdom
Just when you thought you knew all you needed to know about known actives, the rapidly developing field of biosimilars is presenting new challenges and opportunities. Taken from three perspectives, this session will address how establishing biosimilarity advances our understanding of known actives. Ironically, this is done whilst biosimilars themselves are not well understood by key stakeholders, such as physicians, patients and the wider public. Each of the presenters will discuss these points, reflecting on key developments and initiatives underway in both the regulatory and policy arenas in Europe.
Speaker(s)
Biosimilarity: A better definition of terms and concepts
Christian Schneider, DrMed
PharmaLex, Denmark
Head of Biopharma Excellence and Chief Medical Officer (Biopharma)
Mark McCamish, MEd, PMP
Forty Seven Inc., United States
President and Chief Executive Officer
Trust through Engagement: Explaining biosimilarity to a wider audience
Virginia Acha, PhD, MSc
Merck Sharp & Dohme LLC, United Kingdom
AVP, Global Regulatory Policy
Have an account?